Disclosures: Michael Nudo: Nothing to Disclose, Felice Cinque: Nothing to Disclose, Sahar Saeed: Novo Nordisk: Consultant, Amanda Lupu: Nothing to Disclose, James Gazetas: Nothing to Disclose, Luz Ramos Ballesteros: Nothing to Disclose, Wesal Elgretli: Nothing to Disclose, Erica Moodie: Nothing to Disclose, Colleen Price: Nothing to Disclose, Ken Monteith: Nothing to Disclose, Curtis Cooper: Nothing to Disclose, Sharon Walmsley: Nothing to Disclose, Neora Pick: Nothing to Disclose, Melanie Murray: Nothing to Disclose, Nadine Kronfli: Nothing to Disclose, Joseph Cox: Nothing to Disclose, Cecilia Costiniuk: Nothing to Disclose, Alexandra De Pokomandy: Nothing to Disclose, Jean-Pierre Routy: Nothing to Disclose, Marina Klein: Nothing to Disclose, Bertrand Lebouch: Merck Canada: Speaking and Teaching, Gilead: Speaking and Teaching, ViiV healthcare: Consultant, Gilead: ASAP study managed by RI-MUHC, Merck: I score study and core set study managed by RI-MUHC, ViiV: PIVHOT progra mfro patients managed by RI-MUHC, Giada Sebastiani: Novo Nordisk: Consultant, Abbvie: Speaking and Teaching, Merck: Consultant, Gilead: Speaking and Teaching, Theratechnologies Inc.: Grant/Research Support 625 FREE FATTY ACID INDUCES APOPTOSIS VIA LNCRNA NEAT1/MIR-26A/PTEN AXIS IN HEPATIC CELLS Amrendra Kumar Sah 1 Teja Naveen Sata 1 Abdullah Mohit 1 Gopal Sharma 1 Md Ismail 1 Md Musa Hossain 1 Sarita Gupta 2 Sanal Madhusudana Girija 2 Senthil Venugopal 1 , 1 South Asian University, 2 Institute of Liver and Biliary Sciences Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the leading causes of end stage chronic liver disease and HCC
Go back to Canada
Your Investment, Your Future The wellness and IV therapy industry is booming
In the complex world of antioxidants, two players stand out as champions of skin health and overall well-being: glutathione and Vitamin C
